A novel clinical decision aid to support personalized treatment selection for patients with CT1 renal cortical masses: Results from a multi-institutional competing risks analysis including performance status and comorbidity.
Psutka S, Gulati R, Jewett M, Fadaak K, Finelli A, Morgan T, Pierorazio P, Allaf M, Herrin J, Lohse C, Thompson R, Boorjian S, Atwell T, Schmit G, Costello B, Legere L, Shah N, Leibovich B. A novel clinical decision aid to support personalized treatment selection for patients with CT1 renal cortical masses: Results from a multi-institutional competing risks analysis including performance status and comorbidity. Journal Of Clinical Oncology 2020, 38: 610-610. DOI: 10.1200/jco.2020.38.6_suppl.610.Peer-Reviewed Original ResearchCancer-specific mortalityRenal cortical massesCharlson Comorbidity IndexPerformance statusActive surveillancePersonalized treatment selectionCortical massTreatment selectionThermal ablationContemporary multi-institutional cohortTreatment-specific probabilitiesECOG performance statusTreatment-associated complicationsMulti-institutional cohortCause of deathClinical decision aidCause of mortalityCause mortalityComorbidity indexEligible patientsPatient characteristicsComplication ratePatient ageRadiological featuresComplication risk